Skip to page content
Menu
← All available research
GRDX · AUTOMATICALLY IMPORTED SEC FIGURES

ENTERO THERAPEUTICS, INC. (GRDX)
Stock research & financials

Reported business results for SEC issuer CIK 0001604191. These figures are automatically extracted and have not received the manual review applied to our 22 reviewed profiles.

START WITH THE BUSINESS

The annual figures, at a glance.

Annual period ended 2025-12-31. These are historical business results, not current prices or forecasts.

Net profit / loss

-6.39mUSDProfit after expenses; a negative figure is a loss.Original filing ↗

Debt

UnavailableNot verified in this snapshot. Check the balance sheet in the original filing.

Unavailable does not mean zero. Rounded figures are for scanning; detailed values and source dates follow below.

LOOK BEHIND THE NUMBER

Inspect reported figures

Choose a measure, check the periods and follow the filing. This uses the same historical snapshot as the figures above.

Sector & issuer classification

Utilities ↗

Reported industry: Electric & Other Services Combined (SIC 4931). Sector evidence ↗ · checked 2026-11-10. Official SEC SIC mapped to editorial discovery group. A sector is a discovery group, not a security-type or current trading-status verification.

Explore the chart and market statistics

Dividend yield & key stats

Loading statistics for GRDX…

Dividend yield
Unavailable until provider data loads
Market cap
Unavailable until provider data loads
P/E ratio
Unavailable until provider data loads
Earnings per share
Unavailable until provider data loads

Missing data does not mean zero. Coverage varies by listing.

Sources, dates and coverage

Snapshot checked 2026-10-17. This is dated annual data, not a live price, forecast, valuation or confirmation of the latest filing. An issuer may have several listed securities; these are company figures, not separate financial statements for each listing.

Reporting periods and units appear with each figure. Missing measures remain unavailable. Filing dates are shown where supplied by the source; otherwise check the original filing before relying on it.

Check the issuer’s SEC filings ↗

ENTERO THERAPEUTICS, INC.: annual results at a glance

The most recent retained annual period ended 2025-12-31. 4 financial measures are available in this snapshot. Figures below describe the business; they are not a share price.

Changes between retained annual periods

Periods of similar length and matching units only. Restatements, acquisitions and accounting changes can affect comparisons; read the filings for context.

Net income / loss

2024-12-31 → 2025-12-31

-18,059,336 → -6,392,654 USD

Percentage change is not shown when the earlier value is zero or negative.

Bar lengths show magnitude; signed values are labelled above.

Check the underlying filing ↗

Operating cash flow

2024-12-31 → 2025-12-31

-9,217,823 → -5,702,824 USD

Percentage change is not shown when the earlier value is zero or negative.

Bar lengths show magnitude; signed values are labelled above.

Check the underlying filing ↗

Diluted earnings per share

2024-12-31 → 2025-12-31

-15.99 → -4.16 USD/shares

Percentage change is not shown when the earlier value is zero or negative.

Bar lengths show magnitude; signed values are labelled above.

Check the underlying filing ↗

GRDX stock research: questions answered

Use these dated financial results as a starting point, then check the original reports for context.

What was ENTERO THERAPEUTICS, INC.'s reported revenue?

For the annual period ended 2025-12-31, ENTERO THERAPEUTICS, INC. reported revenue of 36,251 USD. This is a historical reported result, not a forecast.

Read the original filing for this figure ↗
What was ENTERO THERAPEUTICS, INC.'s reported net income?

For the annual period ended 2025-12-31, ENTERO THERAPEUTICS, INC. reported net income of -6,392,654 USD. This is a historical reported result, not a forecast.

Read the original filing for this figure ↗
What was ENTERO THERAPEUTICS, INC.'s reported operating cash flow?

For the annual period ended 2025-12-31, ENTERO THERAPEUTICS, INC. reported operating cash flow of -5,702,824 USD. This is a historical reported result, not a forecast.

Read the original filing for this figure ↗
What was ENTERO THERAPEUTICS, INC.'s reported diluted earnings per share?

For the annual period ended 2025-12-31, ENTERO THERAPEUTICS, INC. reported diluted earnings per share of -4.16 USD/shares. This is a historical reported result, not a forecast.

Read the original filing for this figure ↗
Does this page show GRDX's live share price?

No. This page covers historical company financial results. It does not provide a live share price, current valuation or buy/sell recommendation.

Find ENTERO THERAPEUTICS, INC.'s SEC filings and check for newer reports ↗

Understand the figures before comparing stocks

Sources, checks and calculation methods →

Revenue, profit and cash flow explained →

How to check company research and filing dates →

Find another company’s annual financial research →

Annual period ended 2025-12-31

2025-01-01 – 2025-12-31 · Reporting currency USD · filing date: check original source

Annual period ended 2024-12-31

2024-01-01 – 2024-12-31 · Reporting currency USD · filing date: check original source

Revenue

Unavailable

No supported figure in this period

Annual period ended 2023-12-31

2023-01-01 – 2023-12-31 · Reporting currency USD · filing date: check original source

Revenue

Unavailable

No supported figure in this period

Continue your research

Check the original reports, investigate debt, cash flow and dilution, and use the workspace to save your own notes.

Open research workspace ↗
Try free beta